Elife logo

編集者

目次

    更新日: 2024.10.03
    Medical information: Rybelsus

    Important safety information including dosage, side effects, and precautions of Rybelsus.

    Image assets%2Ff84ab7e7f0af4058b5c5065e08214eae%2Fded6bc3d99c44944ab220f418e220c9b

    Dosage & Administration

    ・Take one tablet with water (no more than 120 ml) in the morning.


    ・Do not eat or drink for at least 30 minutes after taking the medication and avoid taking other medications. (Eating at least 30 minutes after taking the medication will increase the absorption of the medication.)


    ・Start by taking 3mg (green), and increase your dosage to 7mg (red) and 14mg (blue), if needed.


    ・If your doctor has instructed you to take a blood test, please follow the doctor’s instructions.


    ・Do not take more than 1 tablet daily.

    Side Effects

    While side effects typically improve on their own, if you notice any unusual symptoms, it's important to take appropriate action, such as stopping the medication and seeking medical treatment.


    The following side effects may occur:

    ・Gastrointestinal disorders (nausea, vomiting, diarrhea), hypoglycemia*1, acute pancreatitis, among others.


    *1: Symptoms of hypoglycemia include weakness, fatigue, intense hunger, cold sweats, pallor, palpitations, tremors, headache, dizziness, nausea, and visual changes.

    Precautions

    ・Do not use if you are pregnant or plan to become pregnant, breastfeeding, or within 3 months postpartum.


    ・Consult your doctor if you are taking other medications.


    ・When visiting other health care providers, please mention that you are taking Rybelsus.


    ・Selling pharmaceuticals without a proper license, including on online sales platforms and apps, may violate Article 24.1 of the Pharmaceutical Affairs Law. To avoid legal issues, please refrain from engaging in such sales activities.

    Approval status in Japan

    ・Rybelsus is approved by the Ministry of Health, Labour and Welfare for the treatment of type 2 diabetes.


    ・Prescription for other purposes such as obesity treatment is not approved in Japan.


    *Medicines prescribed by this department are not covered by the Adverse Reactions Relief System.

    Availability of approved medicines that have the same active ingredients in Japan

    ・In Japan, Wegovy is approved for the treatment of obesity.

    Means of acquisition

    ・Our affiliated clinics purchase Rybelsus through a domestic pharmaceutical distributor.

    Information on safety and approval in other countries

    ・Rybelsus is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of type 2 diabetes.